Letermovir CMV prophylaxis offers survival benefit in hematopoietic cell transplant patients
Francisco Marty, MD, associate professor of medicine at Harvard Medical School and attending physician at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, reviews the efficacy of letermovir as prophylaxis for cytomegalovirus in high-risk hematopoietic cell transplant patients. Previous data from a phase 3 trial showed that letermovir was highly effective at preventing infections in patients who underwent allogeneic hematopoietic cell transplantation (HCT) and were CMV-seropositive at the time of transplant.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063